Compare Cipla with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs VENUS REMEDIES - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA VENUS REMEDIES CIPLA/
VENUS REMEDIES
 
P/E (TTM) x 37.0 -7.8 - View Chart
P/BV x 4.3 0.5 824.2% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 CIPLA   VENUS REMEDIES
EQUITY SHARE DATA
    CIPLA
Mar-20
VENUS REMEDIES
Mar-18
CIPLA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs586126 465.1%   
Low Rs35761 584.0%   
Sales per share (Unadj.) Rs207.0301.8 68.6%  
Earnings per share (Unadj.) Rs18.6-24.9 -74.8%  
Cash flow per share (Unadj.) Rs33.22.5 1,303.3%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs195.5293.3 66.7%  
Shares outstanding (eoy) m806.3512.34 6,534.4%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.30.3 734.5%   
Avg P/E ratio x25.3-3.8 -673.9%  
P/CF ratio (eoy) x14.236.7 38.7%  
Price / Book Value ratio x2.40.3 756.0%  
Dividend payout %21.50-   
Avg Mkt Cap Rs m379,9121,154 32,927.3%   
No. of employees `00025.80.9 2,794.1%   
Total wages/salary Rs m30,270393 7,700.4%   
Avg. sales/employee Rs Th6,459.64,026.1 160.4%   
Avg. wages/employee Rs Th1,171.2425.0 275.6%   
Avg. net profit/employee Rs Th580.2-331.8 -174.9%   
INCOME DATA
Net Sales Rs m166,9493,724 4,482.9%  
Other income Rs m3,44223 15,297.8%   
Total revenues Rs m170,3913,747 4,547.9%   
Gross profit Rs m32,060395 8,120.5%  
Depreciation Rs m11,747338 3,472.2%   
Interest Rs m1,974354 557.0%   
Profit before tax Rs m21,782-275 -7,912.0%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,31232 19,974.7%   
Profit after tax Rs m14,995-307 -4,886.0%  
Gross profit margin %19.210.6 181.1%  
Effective tax rate %29.0-11.5 -252.5%   
Net profit margin %9.0-8.2 -109.0%  
BALANCE SHEET DATA
Current assets Rs m117,0382,638 4,437.2%   
Current liabilities Rs m43,9312,305 1,906.2%   
Net working cap to sales %43.88.9 489.7%  
Current ratio x2.71.1 232.8%  
Inventory Days Days96135 70.7%  
Debtors Days Days8546 183.6%  
Net fixed assets Rs m107,4244,871 2,205.5%   
Share capital Rs m1,613123 1,306.7%   
"Free" reserves Rs m156,0183,496 4,463.2%   
Net worth Rs m157,6303,619 4,355.5%   
Long term debt Rs m23,6931,374 1,723.9%   
Total assets Rs m236,6267,509 3,151.4%  
Interest coverage x12.00.2 5,398.2%   
Debt to equity ratio x0.20.4 39.6%  
Sales to assets ratio x0.70.5 142.3%   
Return on assets %7.20.6 1,136.0%  
Return on equity %9.5-8.5 -112.2%  
Return on capital %12.81.6 811.6%  
Exports to sales %33.00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m56,0360-   
Fx outflow Rs m6,764517 1,309.6%   
Net fx Rs m49,272-517 -9,539.6%   
CASH FLOW
From Operations Rs m30,685514 5,965.1%  
From Investments Rs m1,040-123 -845.2%  
From Financial Activity Rs m-29,488-387 7,617.7%  
Net Cashflow Rs m2,3404 55,719.0%  

Share Holding

Indian Promoters % 16.0 32.9 48.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 0.2 6,777.8%  
FIIs % 23.7 0.6 4,086.2%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 66.4 39.5%  
Shareholders   161,166 20,121 801.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  WYETH  ABBOTT INDIA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Plunged 536 Points Today(Closing)

Extending losses to the fifth straight session, Indian share markets witnessed selling pressure throughout the day today and ended deep in the red.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 28, 2021 03:36 PM

TRACK CIPLA

CIPLA - TTK HEALTHCARE COMPARISON

COMPARE CIPLA WITH

MARKET STATS